Disruptive Trends in Pharma Regulation
2018
While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of scientific advancement in medicine – symbolized by recent radical breakthroughs in all manners of domains from stem cells and CAR-T generation immunotherapy to gene tech and 3D bio-printing – it is clear that regulatory science has struggled to keep pace with the sheer abundance of change.
Through interviews with the heads of some of the world’s top regulatory bodies for medicines, as well as many top companies, this report outlines the major new trends in play as pharma regulation attempts to catch up with science. Topics covered include regulatory convergence between nations, herbal-based medicine, clinical research and much more.
While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of scientific advancement in medicine – symbolized by recent radical breakthroughs in all manners of domains from stem cells and CAR-T generation immunotherapy to gene tech and 3D bio-printing – it is clear that regulatory science has struggled to keep pace with the sheer abundance of change.
Through interviews with the heads of some of the world’s top regulatory bodies for medicines, as well as many top companies, this report outlines the major new trends in play as pharma regulation attempts to catch up with science. Topics covered include regulatory convergence between nations, herbal-based medicine, clinical research and much more.
Sharing Link
or sharing via
